-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yu Heng Pharmaceuticals disclosed today that the company held a board of directors on the 18th authorized Chairman Zhu Jiman and Bow Jing, Changshu City Asia New Investment Management Center (Limited Partnership) signed the "Acquisition Framework Agreement", the company intends to acquire Bow Jing and other holdings of 70% of the Shanghai Yixin Information Technology (Group) Co., Ltd., the transaction price of about 1.6 billion yuan.
According to the announcement, the Group belongs to a third-party collection and outsourcing service organization, for third-party payment institutions (including but not limited to Zhonghui, Lacala, Haike accommodation, pay door-to-door) to expand and sell POS terminal equipment, thereby obtaining the collection platform service fee. Business includes, but is not limited to, bank card collection business, online code-sweeping payment business, UnionPay express payment business, etc., of which the main business is the market-side service business of bank card collection business. Yan Cheng Group by a number of industry-qualified agents, is the industry's first and only successful operation of the agent group, business covers 24 provinces, with a large number of merchant resources and personal user resources, with agents, direct business two models of promotion channels.
From the financial data, the group has experienced rapid expansion over the past year, with total assets of 261 million yuan and owner's equity of 164 million yuan at the end of October 2017, and operating income of 397 million yuan and net profit of 137 million yuan in the first 10 months of this year. At the end of 2016, the group's total assets were only 46.87 million yuan, with owner's equity of 19.78 million yuan, and 2016 full-year operating income was 64.9 million yuan, with a net profit of 16.01 million yuan. At the end of 2016, the group had 15 holding subsidiaries, and 16 new holding subsidiaries were added in the first quarter of this year, the statement said.
Yuheng Pharmaceuticals has set three preconditions for the acquisition: first, the target company already owns 100% of all of its controlling subsidiaries;
to all existing shareholders of the Group, the net profit attributable to the parent company of the target company, audited in 2018, 2019 and 2020, in accordance with the principle of before and after deducting non-recurring profit and loss, was RMB350 million, RMB 550 million and RMB900 million, respectively. (Shanghai Securities News)